Dec 20, 2017 | Densitas Inc., News
See original CBC article here
The Nova Scotia government is touting new hospital software it says can better predict breast cancer risk, but the province is not routinely sharing the results with patients or their family doctors.
In October, software designed by Nova Scotia company Densitas was installed in hospitals throughout the province to automatically record breast density during mammograms.
The idea is to use the technology instead of relying on a radiologist’s eyes because, like cancer, dense breast tissue appears white in mammograms, making it difficult for radiologists to see. A woman with dense breasts also has more dense tissue than fatty, and that means her chances of getting cancer are higher.
But unless a woman specifically asks her doctor to request the breast density recordings from the radiologists, the results are filed away.
Cheryl Stewart-Walsh said women deserve to know that information, along with the potential health risks of having dense breasts.
The Dartmouth, N.S., woman said she still wonders about her examination four years ago. She had noticed some lumps and was told she had dense breasts, but her mammogram came back clear.
Knowledge is power
“If somebody had said to me back then, ‘You have dense breast tissue and it means that you need to be more vigilant because you have a higher risk of breast cancer,’ I would have been doing more regular exams,” she said.
This spring, the 39-year-old noticed a lump in the same spot doctors had first examined. Within weeks, she was diagnosed with breast cancer and has since undergone a lumpectomy, 18 weeks of chemotherapy and 21 rounds of radiation. She just completed cancer treatment last month.
Paula Gordon, a Vancouver-based radiologist with the national advocacy group Dense Breasts Canada, said women deserve to know their breast-density information so they can be more vigilant with self-exams.
Cancer risks
“Knowing your breast density is like knowing that you have high blood pressure or that you have high cholesterol,” Gordon said. “Can you imagine a family doctor taking somebody’s blood pressure and finding it high, and not sharing that information with the patient?”
Approximately 43 per cent of women aged 40 to 74 have dense breast tissue, according to Gordon’s group, which means more than 100,000 women in Nova Scotia could be affected.
Some women with dense breasts have four to six times the risk of getting breast cancer compared with women who don’t have dense breasts, according to the Canadian Cancer Society.
The province says it eventually wants to provide its new software-generated breast-density information automatically to doctors and patients. However, there is currently no “mechanism” or timeline to do so, according to Dr. Sian Iles, a radiologist and medical adviser for the Nova Scotia breast screening program, which is run by Nova Scotia’s Department of Health.
“We have got plans but we haven’t been able to implement that yet,” Iles said. “It’s a very complex health-care system. We’re not in charge of all the variables.”
Years have been spent standardizing the reporting of breast density, Iles said, and every mammogram in Nova Scotia now leads to an automated breast density report.
Each province has different rules around testing and reporting breast density. Quebec requires that a woman’s breast density information be reported, but only to her doctor.
Other provinces, like Ontario and P.E.I., usually require that the information be passed on to a woman’s doctor, and that the patient be informed if her density is over 75 per cent, which is considered extreme.
Until recently, Nova Scotia was the only province that did not require radiologists to record breast density, according to Dense Breasts Canada.
Gordon, the medical adviser with Dense Breasts Canada, said 50 per cent of breast cancers in women with dense breasts are missed on mammograms.
“We see these patients in the clinic,” said Gordon. “They come with a lump in their breast that they have found, sometimes within weeks or months of a negative screening mammogram.
“The lump in their breast … turns out to be not just a cancer, but sometimes a sizable cancer.”
]]>
Nov 30, 2017 | Densitas Inc., News
See original article here
DM-Density personalized breast density reporting software will be offered via vendor neutral artificial intelligence distribution platform
Chicago, IL – November 26, 2017 – Advanced breast imaging analytics provider, Densitas, today announced that it now offers its automated breast density software through EnvoyAI’s scalable distribution platform to facilitate streamlined deployment of its flagship product within hospital networks and clinics. The software, DM-Density, helps radiologists provide tailored, patient-specific follow-up care.
“We’re pleased to offer hospitals and physicians the opportunity to use Densitas’ breast density software either on-premise or in the cloud. We’re committed to providing our customer base with secure access to innovative AI products globally,” said Misha Herscu, CEO, EnvoyAI. “Densitas’ breast density software is a welcome addition to the many clinically useful applications available on the EnvoyAI Exchange.”
“We’re pleased to partner with EnvoyAI to streamline deployment of our automated breast density software to empower health systems to standardize high quality care for women and improve workflow,” said Mohamed Abdolell, CEO, Densitas. “The EnvoyAI platform provides a unique opportunity to rapidly expand our footprint so these important outcomes can be achieved.”
DM-Density is a machine learning application that provides on demand automated breast density assessments at point-of-care. The software analyzes standard digital mammograms and integrates seamlessly with PACS systems. The reports provide radiologists with insights to make better follow-up care decisions consistently and confidently.
About Densitas
Densitas develops machine learning technologies that deliver actionable information for personalized breast health. The technologies address the key challenges facing breast screening, including mammography quality, workflow, compliance and costs, with the aim of improving patient health efficiently and effectively. Densitas has received regulatory clearance to sell its automated breast density assessment software in Canada and the European Union. Learn more.
About EnvoyAI
EnvoyAI provides a developer platform, integrations, and an API interface for algorithm developers, technology partners, and end users. EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. The platform allows users anywhere to access cloud-based algorithms without requiring access to the algorithm code or training data to protect PHI and developer intellectual property. EnvoyAI assists research institutions and emerging AI companies in the translation and commercialization processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians. www.envoyai.com
Media Contact:Alex MorrisDirector, Programs and Regulatory Affairs
Densitas
[email protected]
647-470-4363]]>
